{"pmid":32474037,"title":"Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 infection: Experience at a large NHS Foundation Trust in the UK.","text":["Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 infection: Experience at a large NHS Foundation Trust in the UK.","J Infect","Colton, Hayley","Ankcorn, Michael","Yavuz, Mehmet","Tovey, Leeanne","Cope, Alison","Raza, Mohammad","Keeley, Alexander J","State, Amy","Poller, Bozena","Parker, Matthew","de Silva, Thushan I","Evans, Cariad","32474037"],"journal":"J Infect","authors":["Colton, Hayley","Ankcorn, Michael","Yavuz, Mehmet","Tovey, Leeanne","Cope, Alison","Raza, Mohammad","Keeley, Alexander J","State, Amy","Poller, Bozena","Parker, Matthew","de Silva, Thushan I","Evans, Cariad"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474037","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.061","keywords":["covid19","e gene","pcr","rdrp gene","sars-cov-2","diagnosis"],"locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Diagnosis"],"weight":1,"_version_":1668341932657475584,"score":9.490897,"similar":[{"pmid":32290904,"pmcid":"PMC7160437","title":"Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020.","text":["Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020.","Healthcare workers (HCW) are potentially at increased risk of infection with coronavirus disease (COVID-19) and may transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to vulnerable patients. We present results from staff testing at Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom. Between 16 and 29 March 2020, 1,533 symptomatic HCW were tested, of whom 282 (18%) were positive for SARS-CoV-2. Testing HCW is a crucial strategy to optimise staffing levels during this outbreak.","Euro Surveill","Keeley, Alexander J","Evans, Cariad","Colton, Hayley","Ankcorn, Michael","Cope, Alison","State, Amy","Bennett, Tracy","Giri, Prosenjit","de Silva, Thushan I","Raza, Mohammad","32290904"],"abstract":["Healthcare workers (HCW) are potentially at increased risk of infection with coronavirus disease (COVID-19) and may transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to vulnerable patients. We present results from staff testing at Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom. Between 16 and 29 March 2020, 1,533 symptomatic HCW were tested, of whom 282 (18%) were positive for SARS-CoV-2. Testing HCW is a crucial strategy to optimise staffing levels during this outbreak."],"journal":"Euro Surveill","authors":["Keeley, Alexander J","Evans, Cariad","Colton, Hayley","Ankcorn, Michael","Cope, Alison","State, Amy","Bennett, Tracy","Giri, Prosenjit","de Silva, Thushan I","Raza, Mohammad"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290904","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2807/1560-7917.ES.2020.25.14.2000433","keywords":["covid-19","sars-cov-2","diagnostic test","healthcare workers"],"locations":["United Kingdom","United Kingdom"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138494347509761,"score":60.885605},{"pmid":32132196,"pmcid":"PMC7180250","title":"Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.","text":["Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.","On 31 December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated coronavirus disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time reverse transcription-PCR (RT-PCR) assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay, which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 50% tissue culture infective doses [TCID50]/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRp-P2-negative specimens (119/273 [43.6%] versus 77/273 [28.2%]; P < 0.001), including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21 x 10(4) RNA copies/ml (range, 2.21 x 10(2) to 4.71 x 10(5) RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19.","J Clin Microbiol","Chan, Jasper Fuk-Woo","Yip, Cyril Chik-Yan","To, Kelvin Kai-Wang","Tang, Tommy Hing-Cheung","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tsoi, Hoi-Wah","Choi, Garnet Kwan-Yue","Tam, Anthony Raymond","Cheng, Vincent Chi-Chung","Chan, Kwok-Hung","Tsang, Owen Tak-Yin","Yuen, Kwok-Yung","32132196"],"abstract":["On 31 December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated coronavirus disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time reverse transcription-PCR (RT-PCR) assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay, which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 50% tissue culture infective doses [TCID50]/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRp-P2-negative specimens (119/273 [43.6%] versus 77/273 [28.2%]; P < 0.001), including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21 x 10(4) RNA copies/ml (range, 2.21 x 10(2) to 4.71 x 10(5) RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19."],"journal":"J Clin Microbiol","authors":["Chan, Jasper Fuk-Woo","Yip, Cyril Chik-Yan","To, Kelvin Kai-Wang","Tang, Tommy Hing-Cheung","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tsoi, Hoi-Wah","Choi, Garnet Kwan-Yue","Tam, Anthony Raymond","Cheng, Vincent Chi-Chung","Chan, Kwok-Hung","Tsang, Owen Tak-Yin","Yuen, Kwok-Yung"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32132196","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1128/JCM.00310-20","keywords":["covid-19","pcr","sars","wuhan","coronavirus","diagnostic","emerging","virus"],"locations":["Wuhan","China","China","RdRp","Vitro"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492785131521,"score":60.31052},{"pmid":32403007,"title":"Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic.","text":["Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic.","OBJECTIVES: To evaluate the reliability of self-collection for SARS-CoV-2 and other respiratory viruses because swab collections for SARS-CoV-2 put health workers at risk of infection and require use of personal protective equipment (PPE). METHODS: In a prospective study, patients from two states in Australia attending dedicated COVID-19 collection clinics were offered the option to first self-collect (SC) nasal and throat swabs (SCNT) prior to health worker collect (HC) using throat and nasal swabs (Site 1) or throat and nasopharyngeal swabs (Site 2). Samples were analysed for SARS-CoV-2 as well as common respiratory viruses. Concordance of results between methods was assessed using Cohen's kappa (kappa) and Cycle threshold (Ct) values were recorded for all positive results as a surrogate measure for viral load. RESULTS: Of 236 patients sampled by HC and SC, 25 had SARS-CoV-2 (24 by HC and 25 by SC) and 63 had other respiratory viruses (56 by HC and 58 by SC). SC was highly concordant with HC (kappa=0.890) for all viruses including SARS-CoV-2 and more concordant than HC to positive results by any method (kappa=0.959 vs 0.933). Mean SARS-CoV-2 E-gene and N-gene, rhinovirus and parainfluenza Ct values did not differ between HC and SCNT. CONCLUSIONS: Self-collection of nasal and throat swabs offers a reliable alternative to health worker collection for the diagnosis of SARS-CoV-2 and other respiratory viruses and provides patients with easier access to testing, reduces exposure of the community and health workers to those being tested and reduces requirement for PPE.","J Clin Virol","Wehrhahn, Michael C","Robson, Jennifer","Brown, Suzanne","Bursle, Evan","Byrne, Shane","New, David","Chong, Smathi","Newcombe, James P","Siversten, Terri","Hadlow, Narelle","32403007"],"abstract":["OBJECTIVES: To evaluate the reliability of self-collection for SARS-CoV-2 and other respiratory viruses because swab collections for SARS-CoV-2 put health workers at risk of infection and require use of personal protective equipment (PPE). METHODS: In a prospective study, patients from two states in Australia attending dedicated COVID-19 collection clinics were offered the option to first self-collect (SC) nasal and throat swabs (SCNT) prior to health worker collect (HC) using throat and nasal swabs (Site 1) or throat and nasopharyngeal swabs (Site 2). Samples were analysed for SARS-CoV-2 as well as common respiratory viruses. Concordance of results between methods was assessed using Cohen's kappa (kappa) and Cycle threshold (Ct) values were recorded for all positive results as a surrogate measure for viral load. RESULTS: Of 236 patients sampled by HC and SC, 25 had SARS-CoV-2 (24 by HC and 25 by SC) and 63 had other respiratory viruses (56 by HC and 58 by SC). SC was highly concordant with HC (kappa=0.890) for all viruses including SARS-CoV-2 and more concordant than HC to positive results by any method (kappa=0.959 vs 0.933). Mean SARS-CoV-2 E-gene and N-gene, rhinovirus and parainfluenza Ct values did not differ between HC and SCNT. CONCLUSIONS: Self-collection of nasal and throat swabs offers a reliable alternative to health worker collection for the diagnosis of SARS-CoV-2 and other respiratory viruses and provides patients with easier access to testing, reduces exposure of the community and health workers to those being tested and reduces requirement for PPE."],"journal":"J Clin Virol","authors":["Wehrhahn, Michael C","Robson, Jennifer","Brown, Suzanne","Bursle, Evan","Byrne, Shane","New, David","Chong, Smathi","Newcombe, James P","Siversten, Terri","Hadlow, Narelle"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32403007","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104417","keywords":["covid-19","diagnosis","pcr","respiratory viruses","sars-cov-2","self-collection"],"locations":["Australia"],"countries":["Australia"],"countries_codes":["AUS|Australia"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1666714494916624385,"score":51.59666},{"pmid":32504946,"title":"Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance.","text":["Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance.","BACKGROUND: High-throughput assays for the SARS-CoV-2 virus are critical to increasing test capacity and slowing the spread of COVID-19. Abbott Molecular developed and received emergency use authorization (EUA) to deploy the new RealTime SARS-CoV-2 assay, run on the automated m2000sp/rt system. OBJECTIVE: To evaluate analytical and clinical performance of the RealTime SARS-CoV-2 assay compared to the SARS-CoV-2 CDC-based laboratory developed test (LDT) in clinical use by the University of Washington Clinical Virology Laboratory (UW Virology). METHODS: RealTime SARS-CoV-2 assay limit of detection (LOD) was evaluated by testing two dilution panels of 60 replicates each. Cross-reactivity was evaluated by testing 24 clinical samples positive for various nonSARS-CoV-2 respiratory viruses. Clinical performance was evaluated using 30 positive and 30 negative SARS-CoV-2 clinical samples previously tested using the UW Virology SARS-CoV-2 LDT. RESULTS: Exceeding the 100 copies/mL LOD reported in the RealTime SARS-CoV-2 assay EUA product insert, 19 of 20 replicates were detected at 50 copies/mL and 16 of 20 replicates were detected at 25 copies/mL. All clinical samples positive for 24 nonSARS-CoV-2 respiratory viruses were SARS-CoV-2 negative on the RealTime SARS-CoV-2 assay. The assay had high sensitivity (93%) and specificity (100%) for detecting SARS-CoV-2 in clinical samples. Two positive samples that tested negative with the RealTime SARS-CoV-2 assay had cycle numbers of 35.94 or greater and required dilution prior to testing. One of these samples was also inconclusive on the SARS-CoV-2 LDT. CONCLUSION: The RealTime SARS-CoV-2 assay is acceptable for clinical use. With the high-throughput, fully automated m2000 system, this assay will accelerate the pace of SARS-CoV-2 testing.","J Clin Virol","Degli-Angeli, Emily","Dragavon, Joan","Huang, Meei-Li","Lucic, Danijela","Cloherty, Gavin","Jerome, Keith R","Greninger, Alexander L","Coombs, Robert W","32504946"],"abstract":["BACKGROUND: High-throughput assays for the SARS-CoV-2 virus are critical to increasing test capacity and slowing the spread of COVID-19. Abbott Molecular developed and received emergency use authorization (EUA) to deploy the new RealTime SARS-CoV-2 assay, run on the automated m2000sp/rt system. OBJECTIVE: To evaluate analytical and clinical performance of the RealTime SARS-CoV-2 assay compared to the SARS-CoV-2 CDC-based laboratory developed test (LDT) in clinical use by the University of Washington Clinical Virology Laboratory (UW Virology). METHODS: RealTime SARS-CoV-2 assay limit of detection (LOD) was evaluated by testing two dilution panels of 60 replicates each. Cross-reactivity was evaluated by testing 24 clinical samples positive for various nonSARS-CoV-2 respiratory viruses. Clinical performance was evaluated using 30 positive and 30 negative SARS-CoV-2 clinical samples previously tested using the UW Virology SARS-CoV-2 LDT. RESULTS: Exceeding the 100 copies/mL LOD reported in the RealTime SARS-CoV-2 assay EUA product insert, 19 of 20 replicates were detected at 50 copies/mL and 16 of 20 replicates were detected at 25 copies/mL. All clinical samples positive for 24 nonSARS-CoV-2 respiratory viruses were SARS-CoV-2 negative on the RealTime SARS-CoV-2 assay. The assay had high sensitivity (93%) and specificity (100%) for detecting SARS-CoV-2 in clinical samples. Two positive samples that tested negative with the RealTime SARS-CoV-2 assay had cycle numbers of 35.94 or greater and required dilution prior to testing. One of these samples was also inconclusive on the SARS-CoV-2 LDT. CONCLUSION: The RealTime SARS-CoV-2 assay is acceptable for clinical use. With the high-throughput, fully automated m2000 system, this assay will accelerate the pace of SARS-CoV-2 testing."],"journal":"J Clin Virol","authors":["Degli-Angeli, Emily","Dragavon, Joan","Huang, Meei-Li","Lucic, Danijela","Cloherty, Gavin","Jerome, Keith R","Greninger, Alexander L","Coombs, Robert W"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504946","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jcv.2020.104474","keywords":["covid-19","coronavirus","eua","high-throughput assay","pcr","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1668892488276901890,"score":47.778793},{"pmid":32344058,"pmcid":"PMC7195012","title":"COVID-19 diagnostic process in mainland China: the math beyond pneumonia.","text":["COVID-19 diagnostic process in mainland China: the math beyond pneumonia.","J Allergy Clin Immunol","Wu, Feng","Huang, Weishan","32344058"],"journal":"J Allergy Clin Immunol","authors":["Wu, Feng","Huang, Weishan"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344058","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaci.2020.04.015","keywords":["covid-19","ct scan","pcr","sars-cov-2","antibody","diagnosis","test"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495787204609,"score":46.69021}]}